Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunic Inc IMUX

Healthcare Biotechnology
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively,... see more

Recent & Breaking News (NDAQ:IMUX)

Immunic to Participate in Industry and Scientific Conferences in June

PR Newswire May 28, 2024

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire May 8, 2024

Immunic to Participate in Investor and Scientific Conferences in May

PR Newswire May 6, 2024

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

PR Newswire May 1, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

PR Newswire April 30, 2024

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

PR Newswire April 4, 2024

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

PR Newswire March 20, 2024

Immunic to Participate in Investor and Scientific Conferences in March

PR Newswire March 7, 2024

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

PR Newswire February 29, 2024

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

PR Newswire February 22, 2024

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

PR Newswire February 15, 2024

Immunic to Participate in Investor and Scientific Conferences in February

PR Newswire February 1, 2024

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

PR Newswire January 5, 2024

Immunic, Inc. Announces Private Placement of up to $240 Million

PR Newswire January 5, 2024

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

PR Newswire November 21, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire November 14, 2023

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update

PR Newswire November 7, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

PR Newswire November 2, 2023

Immunic to Participate in Scientific and Industry Conferences in November

PR Newswire October 26, 2023

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

PR Newswire October 16, 2023